BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies announces the installation of its PURE EP™ System at HCA Healthcare-operated Westside Regional Medical Center in Florida to enhance arrhythmia care. This facility, recognized for its electrophysiology program, adds to BioSig's clinical reach in Florida, which now includes partnerships with notable centers like Mayo Clinic. Over 73 physicians have utilized the PURE EP™ System in more than 1750 patient cases, showing a 75% improvement in signal quality, critical for cardiac procedures.

BioSig Technologies (Nasdaq: BSGM) announced a conference call scheduled for December 21, 2021, at 2 PM ET to discuss its innovative signal processing platform aimed at improving ECG and intra-cardiac signal fidelity. The call will be accessible via U.S. toll-free and international numbers. The PURE EP (tm) System, BioSig's FDA-cleared device, has shown a 75% improvement in signal quality in clinical studies. With increasing cases of atrial fibrillation, the company aims to enhance cardiac care efficiency. A webcast replay will be available following the call.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced that Executive Vice President Natasha Drapeau will present at the Benzinga All Access event on December 14, 2021, at 9:40 am EST. The company has seen solid performance with the first commercial sales of its PURE EP™ System, completing approximately 1800 patient cases. The device aims to enhance cardiac signal quality, with clinical data showing a 75% improvement over conventional sources. Atrial fibrillation affects millions and incurs significant healthcare costs, highlighting the demand for innovative solutions.

BioSig Technologies has appointed Gray Fleming as Chief Commercial Officer to enhance its market presence in electrophysiology. With over 20 years of healthcare experience, including leadership roles at Abbott Laboratories, Fleming aims to leverage his expertise to boost sales and market share of the PURE EP™ System, a non-invasive device designed for cardiac procedures. The company reports positive clinical data, showing a 75% improvement in signal quality. BioSig is currently focused on launching the PURE EP™ in key U.S. markets, including the Northeast, Texas, and Florida.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced its participation in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2, 2021. The company's leadership will update investors on the rollout of their FDA-cleared PURE EP™ System, which enhances procedural efficiency in cardiac electrophysiology. Over 1700 patient cases have been completed by 73 physicians using this system. The event will also discuss results from a recent clinical trial during a roundtable on November 18, 2021.

BioSig Technologies (NASDAQ: BSGM) announced a partnership with the Technion Research & Development Foundation for AI-driven research on atrial fibrillation procedures. The feasibility study will utilize data from BioSig's PURE EP(tm) System to develop predictive algorithms for arrhythmia care. Atrial fibrillation affects over 33 million globally, with significant healthcare costs. BioSig's technology aims to enhance procedural efficiency in cardiac electrophysiology, with ongoing clinical data supporting its effectiveness.

BioSig Technologies (Nasdaq: BSGM) will host a live roundtable webinar on November 18, 2021, discussing results from the PURE EP 2.0 study recently published in the Journal of Cardiovascular Electrophysiology. The event, titled “PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications,” will feature experts Andrea Natale, Amin Al-Ahmad, and Wendy Tzou, who will review the impact of high-fidelity signals on cardiac ablation procedures. The study reported a 75% improvement in intracardiac signal quality and a 93% consensus among blinded reviewers.

BioSig Technologies has announced the installation of its PURE EP™ System at the highly-ranked Medical City Heart Hospital in Dallas, TX, marking its 17th installation and fifth in Texas. The facility focuses on advanced cardiovascular care, making it an ideal site for the technology aimed at improving ECG signal fidelity. Over 71 physicians have already utilized the system in over 1600 patient cases. A recent multi-center study published in the Journal of Cardiovascular Electrophysiology showed a 75% improvement in signal quality using the PURE EP™ System.

BioSig Technologies announces the installation of a PURE EP™ System at Beth Israel Deaconess Medical Center, increasing its installed centers to 16. The evaluation is expected to begin in December 2021. To date, over 71 physicians have conducted more than 1,600 cases with the system, indicating growing adoption. Clinical data shows a 75% improvement in intracardiac signal quality. With 33 million people affected by atrial fibrillation globally, BioSig aims to capitalize on this significant market through its innovative technology.